Literature DB >> 28833326

Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States.

Neehar D Parikh1, Wesley J Marrero2, Jingyuan Wang2, Justin Steuer1, Elliot B Tapper1, Monica Konerman1, Amit G Singal3, David W Hutton2,4, Eunshin Byon2, Mariel S Lavieri2.   

Abstract

Nonalcoholic steatohepatitis (NASH) cirrhosis is the fastest growing indication for liver transplantation (LT) in the United States. We aimed to determine the temporal trend behind the rise in obesity and NASH-related additions to the LT waitlist in the United States and make projections for future NASH burden on the LT waitlist. We used data from the Organ Procurement and Transplantation Network database from 2000 to 2014 to obtain the number of NASH-related LT waitlist additions. The obese population in the United States from 2000 to 2014 was estimated using data from the U.S. Census Bureau and the National Health and Nutrition Examination Survey. Based on obesity trends, we established a time lag between obesity prevalence and NASH-related waitlist additions. We used data from the U.S. Census Bureau on population projections from 2016 to 2030 to forecast obesity estimates and NASH-related LT waitlist additions. From 2000 to 2014, the proportion of obese individuals significantly increased 44.9% and the number of NASH-related annual waitlist additions increased from 391 to 1,605. Increase in obesity prevalence was strongly associated with LT waitlist additions 9 years later in derivation and validation cohorts (R2 = 0.9). Based on these data, annual NASH-related waitlist additions are anticipated to increase by 55.4% (1,354-2,104) between 2016 and 2030. There is significant regional variation in obesity rates and in the anticipated increase in NASH-related waitlist additions (P < 0.01).
Conclusion: We project a marked increase in demand for LT for NASH given population obesity trends. Continued public health efforts to curb obesity prevalence are needed to reduce the projected future burden of NASH. (Hepatology 2017).
Copyright © 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 28833326     DOI: 10.1002/hep.29473

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  38 in total

1.  Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases.

Authors:  Raja R Narayan; Jennifer W Harris; Joanne F Chou; Mithat Gönen; Fei Bao; Jinru Shia; Peter J Allen; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; Nancy E Kemeny; T Peter Kingham; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2019-10-15       Impact factor: 5.344

2.  Bariatric surgery to achieve transplant in end-stage organ disease patients: A systematic review and meta-analysis.

Authors:  Babak J Orandi; Joshua W Purvis; Robert M Cannon; A Blair Smith; Cora E Lewis; Norah A Terrault; Jayme E Locke
Journal:  Am J Surg       Date:  2020-06-13       Impact factor: 2.565

3.  Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis.

Authors:  Elliot B Tapper; Devin Aberasturi; Zhe Zhao; Chia-Yang Hsu; Neehar D Parikh
Journal:  Aliment Pharmacol Ther       Date:  2020-05-03       Impact factor: 8.171

Review 4.  Obstructive Sleep Apnea and the Liver.

Authors:  Malav P Parikh; Niyati M Gupta; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2019-05       Impact factor: 6.126

Review 5.  Contemporary Epidemiology of Cirrhosis.

Authors:  Jad A Baki; Elliot B Tapper
Journal:  Curr Treat Options Gastroenterol       Date:  2019-06

6.  Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program.

Authors:  Monica A Konerman; Aashesh Verma; Betty Zhao; Amit G Singal; Anna S Lok; Neehar D Parikh
Journal:  Liver Transpl       Date:  2019-03       Impact factor: 5.799

Review 7.  Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.

Authors:  Alisa Likhitsup; Neehar D Parikh
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

8.  In-Hospital mortality varies by procedure type among cirrhosis surgery admissions.

Authors:  Nadim Mahmud; Zachary Fricker; Marina Serper; David E Kaplan; Kenneth D Rothstein; David S Goldberg
Journal:  Liver Int       Date:  2019-06-17       Impact factor: 5.828

Review 9.  Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant.

Authors:  Anchalia Chandrakumaran; Mohammad Shadab Siddiqui
Journal:  Gastroenterol Clin North Am       Date:  2020-03       Impact factor: 3.806

10.  Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists.

Authors:  Elliot B Tapper; Rohit Loomba
Journal:  Hepatology       Date:  2018-04-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.